Literature DB >> 22740869

Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1.

Zhigang Bai1, Zhongtao Zhang, Xiang Qu, Wei Han, Xuemei Ma.   

Abstract

The purpose of this study was to determine the role of taxol resistance gene 1 (TXR1) in a taxol-resistant breast cancer cell line. Expression levels of TXR1 and thrombospondin-1 (TSP1) were detected by RT-PCR and Western blot analysis. In MCF-7 cells transfected with TXR1 plasmids, the expression of a number of drug resistance genes was monitored, as well as cell proliferation. MCF-7 cells were also transiently transfected with a chemically synthesized small interfering RNA (siRNA) targeting TXR1. Taxol concentrations varying from 0.6 to 6 μg/ml were shown to inhibit the proliferation of MCF-7 cells in a time- and dose-dependent manner by arresting cells in the G2/M phase. Additionally, 0.06 μg/ml taxol was used to establish a taxol-resistant MCF-7 cell line, MCF-7/T. When TXR1 was exogenously expressed, a taxol-resistant phenotype was further induced and the expression levels of BCRP, GSTP1 and MVP increased. Transient transfection of TXR1-targeting siRNAs was shown to restore the chemosensitivity of MCF-7 cells. These results suggest that an increased expression of TXR1 is a novel mechanism for reversing the taxol resistance of breast cancer cells.

Entities:  

Year:  2011        PMID: 22740869      PMCID: PMC3362456          DOI: 10.3892/ol.2011.416

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

Review 1.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 2.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 3.  TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes?

Authors:  Renée van Amerongen; Anton Berns
Journal:  Genes Dev       Date:  2006-08-01       Impact factor: 11.361

4.  Breast-cancer therapy--looking back to the future.

Authors:  Anne Moore
Journal:  N Engl J Med       Date:  2007-10-11       Impact factor: 91.245

5.  Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells.

Authors:  Y Lavie; H t Cao; A Volner; A Lucci; T Y Han; V Geffen; A E Giuliano; M C Cabot
Journal:  J Biol Chem       Date:  1997-01-17       Impact factor: 5.157

6.  Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway.

Authors:  J E Nör; R S Mitra; M M Sutorik; D J Mooney; V P Castle; P J Polverini
Journal:  J Vasc Res       Date:  2000 May-Jun       Impact factor: 1.934

Review 7.  Molecular mechanisms of drug resistance.

Authors:  D B Longley; P G Johnston
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

8.  Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.

Authors:  Ozgur Kutuk; Anthony Letai
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 9.  Taxanes, microtubules and chemoresistant breast cancer.

Authors:  Barbara T McGrogan; Breege Gilmartin; Desmond N Carney; Amanda McCann
Journal:  Biochim Biophys Acta       Date:  2007-11-12

10.  Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines.

Authors:  L M Greenberger; L Lothstein; S S Williams; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

View more
  5 in total

1.  TXR1 and TSP1 expression varies by the molecular subtypes of breast cancer patients who received previous docetaxel-based first-line chemotherapy.

Authors:  Huiming Zhang; Xiang Qu; Xuemei Ma; Tingting Wang; Yao Yang; Zhicheng Ge; Zhongtao Zhang; Zhigang Bai; Yinguang Gao; Zhu Yuan; Zihan Wang
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-12

2.  Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer.

Authors:  Prarthana Gopinath; Sridevi Veluswami; Gopal Gopisetty; Shirley Sundersingh; Swaminathan Rajaraman; Rajkumar Thangarajan
Journal:  Breast Cancer Res Treat       Date:  2022-05-21       Impact factor: 4.872

3.  Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo.

Authors:  Tasleem Arif; Lilia Vasilkovsky; Yael Refaely; Alexander Konson; Varda Shoshan-Barmatz
Journal:  Mol Ther Nucleic Acids       Date:  2014-04-29       Impact factor: 10.183

Review 4.  Small interfering RNA-based molecular therapy of cancers.

Authors:  Wei Guo; Wangbing Chen; Wendan Yu; Wenlin Huang; Wuguo Deng
Journal:  Chin J Cancer       Date:  2013-01-18

5.  Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin.

Authors:  Liancheng Liu; Zhigang Bai; Xuemei Ma; Tingting Wang; Yao Yang; Zhongtao Zhang
Journal:  Exp Ther Med       Date:  2016-01-13       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.